Tag Archives: CONCORD

Multitest Deploys aPriori Product Cost Management Platform

By Business Wirevia The Motley Fool

Filed under:

Multitest Deploys aPriori Product Cost Management Platform

Semiconductor test equipment maker gains early cost visibility to reduce product costs and accelerate time to market

CONCORD, Mass.–(BUSINESS WIRE)– aPriori, a provider of enterprise product cost management software solutions, today announced that Multitest, one of the world’s leading manufacturers of test equipment for integrated semiconductor chips, has selected aPriori’s platform to increase the visibility of product cost information for new product introductions and throughout its product lifecycles. The company expects to reduce product costs, accelerate time to market for new products, and collaborate more effectively with suppliers on sourced parts as a result.

Multitest provides its customers with highly innovative test handling and test interface solutions, custom-tailored to fit their individual needs and requirements. Getting new products to market on time and on budget are critical to its success and the company will use aPriori in design engineering, sourcing and cost engineering to support these goals.

The company’s design engineers will use the software to quickly and easily compare the cost of different product design alternatives and understand the cost impact of different design options as they happen. As changes are made, or new product specs are introduced, aPriori will automatically and immediately re-assess and provide updated product costs. This will enable Multitest’s engineers to evaluate more design options, attack cost earlier in the product lifecycle and make more informed design and production decisions to reduce product costs from the start. aPriori will also provide sourcing professionals with a standard tool for detailed “should cost” information to help evaluate make vs. buy decisions, work with suppliers more efficiently and reduce the time it takes to get cost estimates back from them. Multitest will also use the aPriori software to evaluate more cost reduction alternatives in cost engineering activities and conduct bulk cost analysis to identify parts’ costs that are out of line with industry standards.

“Our product strategy is focused on doing things right the first time to accelerate our time to market and reduce the time and cost for expensive re-work,” said Mr. Michael Kohl, head of global supply chain management for Multitest. “The aPriori software gives our teams immediate access to product cost information to support their design and sourcing decisions from the earliest stages of product development through production. This will enable greater innovation in new product design and increase our advantage in a very competitive marketplace.”

…read more
Source: FULL ARTICLE at DailyFinance

Cerus Signs INTERCEPT Platelet Agreements With Two Key Blood Component Suppliers in Germany and Aust

By Business Wirevia The Motley Fool

Filed under:

Cerus Signs INTERCEPT Platelet Agreements With Two Key Blood Component Suppliers in Germany and Austria

  • TILAK, University Clinics, Regional Hospital Innsbruck (LKI), one of the largest hospitals in Austria, signs one year agreement for Cerus’ INTERCEPT platelet system.
  • ZIT GmbH Hamburg (Zentralinstitut Hamburg), the largest in-house blood component supplier of the German Asklepios Group, signs four year agreement for the INTERCEPT Blood System for pathogen inactivation of platelet components.

CONCORD, Calif.–(BUSINESS WIRE)– Cerus Corporation (NAS: CERS) announced today that the TILAK, University Clinics, Regional Hospital Innsbruck (LKI) in Austria and ZIT GmbH Hamburg in Germany, signed one and four year purchase agreements, respectively, for the INTERCEPT Blood System for platelets.

LKI is one of the largest hospitals in Austria, with its Central Institute for Blood Transfusion supplying an estimated 6,000 platelet units annually to the federal state of Tyrol. LKI is the second facility in Austria to adopt INTERCEPT for platelets. Together with the General Hospital of Vienna (AKH), an estimated total of 12,000 platelet units, or 30% of the Austrian platelet market, could be treated with INTERCEPT. Implementation of the INTERCEPT platelet system at LKI is expected to start in March 2013.

ZIT Hamburg supplies roughly 10,000 platelet units annually and is the largest in-house blood component supplier to the Asklepios Group, one of the three largest operators of private hospitals in Germany. Implementation is expected to occur upon ZIT Hamburg’s receipt of regulatory approval from the Paul-Ehrlich-Institut to produce INTERCEPT-treated platelets.

“Considering the inherent limitations and increasing cost of the current testing strategies used for platelets, we believe the INTERCEPT Blood System for platelets offers a strong value proposition that combines patient safety with commercial benefits,” stated O. Schertges, CEO of the ZIT Hamburg.

“We believe the breadth of clinical and routine-use data for INTERCEPT platelets accumulated over the last 10 years may have positively influenced the decisions made by LKI and ZIT Hamburg,” said William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “It is this clinical experience and hemovigilance data that led to FDA‘s recent agreement to allow Cerus to proceed with a modular PMA submission for INTERCEPT platelets without the need to conduct another prospective clinical trial.”

ABOUT CERUS

Cerus Corporation is a biomedical products …read more
Source: FULL ARTICLE at DailyFinance